Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD-100 plus Doxorubicin in Advanced Soft Tissue Sarcomas
NCT07027423Phase 1Not yet recruiting
- Sponsor
- University Health Network
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of BOLD-100 in soft tissue sarcoma (STS), leiomyosarcoma (LMS), dedifferentiated liposarcoma (DDL) and 2 more (5 arms), sponsored by University Health Network. Primary endpoints: Incidence of Dose Limiting Toxicities, Rate of Adverse Events and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
BOLD-100
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)dedifferentiated liposarcoma (DDL)undifferentiated pleomorphic sarcoma (UPS)myxofibrosarcoma (MFS)
Beyond the preview
Go deeper on NCT07027423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027423.